A “real-world” observational, nonrandomized analysis of the Food and Drug Administration’s adverse reporting system59 including 7,712 adverse events also reported an increased risk of venous thromboembolism (OR: 1.8; 95% CI: 1.12-2.89) in combination therapy compared with BRAF inhibitor monotherapy. The gene discussed is BRAF; the disease is venous thromboembolism.